J&J Seeks FDA Approval for Nipocalimab

Johnson & Johnson has officially filed for approval from the U.S. Food and Drug Administration (FDA) for its proposed autoimmune drug, nipocalimab. The drug is intended for the treatment of generalized myasthenia gravis, a chronic neuromuscular disease. This condition is known to cause weakness in the voluntary muscles. The application submitted by Johnson & Johnson is a Biologics License Application, which is a necessary step for the approval of the drug.